News
November 29, 2021
Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3Kα and EGFR Exon 20, Two Established Cancer Drivers with Broad Therapeutic Applicability
— Rapid discovery of lead compounds driven by Scorpion’s Precision Oncology 2.0 strategy, and enabled by its fully integrated drug-hunting platform — — Both mutant PI3Kα...November 22, 2021
Scorpion Therapeutics Announces Appointment of Brian Piper as Chief Financial Officer
BOSTON, Mass. – November 22, 2021 – Scorpion Therapeutics, Inc. (“Scorpion”), a next-generation oncology company whose goal is to develop best- and first-in-class precision medicines for...October 25, 2021
Scorpion Therapeutics Expands Executive Leadership Team with Three Key Appointments
– Kristin Schuhwerk joins as Chief Operating Officer – – Andrew Fedder joins as General Counsel – – Adam Friedman, M.D., Ph.D. promoted to President, Corporate...IN THE MEDIA
Endpoints (Subscription Required) | September 22, 2021
Scorpion Therapeutics was named as one of the 2021 Endpoints 11, a group of the most promising up-and-coming private biotechnology companies.STAT (Subscription Required) | July 9, 2021
Scorpion Therapeutics hired Axel Hoos as chief executive officer. Previously, he worked at GlaxoSmithKline, where he was senior vice president of R&D governance chair and therapeutic area...Boston Business Journal | July 9, 2021
Just eight months out of stealth, precision medicine startup Scorpion Therapeutics has netted a big fish in Axel Hoos, the head of oncology at GlaxoSmithKline plc,...Scrip (Subscription Required) | July 7, 2021
Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10...BioCentury (Subscription Required) | July 7, 2021
GSK is losing one of the principal architects of its oncology renaissance as immuno-oncology pioneer Axel Hoos prepares to leave the company for his first CEO...Fierce Biotech | July 7, 2021
After leading oncology teams at GlaxoSmithKline and Bristol Myers Squibb, Axel Hoos, M.D., Ph.D., is heading back to biotech.Endpoints | July 7, 2021
Axel Hoos has long kept the flame alive at GlaxoSmithKline’s oncology division, enduring lean days after the British pharma ditched its late-stage pipeline to Novartis and...Fierce Biotech | January 12, 2021
Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.Boston Globe | January 12, 2021
Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.Endpoints News | January 12, 2021
Whatever investors have peeped about Gary Glick and Keith Flaherty’s game plan to bring about Precision Oncology 2.0, it’s good enough for a $162 million infusion into Scorpion Therapeutics just weeks after its $108 million Series A. Media Contact
Ravi Moorthy
Scorpion Therapeutics
ravi@scorpiontx.com
Investor Contact
Hanna Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com